DigestRedComo funciona
Red
/
Empresas
Ge
No verificado

GenSight Biologics S.A.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaÓpticaSalud

12 Comunicados de prensa

Ver todos los comunicados de prensa
22/12/2025
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Óptica
GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0
22/12/2025
Industria
Salud
Biotecnología
Farmacéutica
Óptica
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0
28/08/2025
Biotecnología
Farmacéutica
Salud
Mercado de valores
Finanzas
Web y redes sociales
Telefonía
GenSight Biologics Postpones Release of 2025 Half-Year Financial Results
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0
08/04/2025
Biotecnología
Salud
Farmacéutica
Óptica
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0
27/02/2025
Biotecnología
Salud
Farmacéutica
Óptica
Mercado de valores
GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0
15/01/2025
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Óptica
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0
18/12/2024
Biotecnología
Farmacéutica
Óptica
Salud
GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0
13/11/2024
Industria
Salud
Biotecnología
Farmacéutica
Óptica
GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0
28/10/2024
GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0
24/10/2024
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Óptica
GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update
Fuente
GenSight Biologics S.A.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0